Revolution Medicines Pancreatic Cancer Drug Daraxonrasib Succeeds in Late-Stage Trial

r/singularity·low signal

Revolution Medicines announced its pancreatic cancer drug daraxonrasib succeeded in a late-stage clinical trial, hitting 165 upvotes on r/singularity. Pancreatic cancer has one of the lowest survival rates of any cancer (5-year survival ~12%), making any late-stage trial success notable. While not directly AI-related, the computational drug discovery pipeline that identified daraxonrasib's RAS inhibition mechanism reflects the broader trend of AI-accelerated pharmaceutical research.